0.834
-0.43 (-33.81%)
| Previous Close | 1.26 |
| Open | 0.978 |
| Volume | 11,698,767 |
| Avg. Volume (3M) | 1,823,392 |
| Market Cap | 60,297,732 |
| Price / Book | 8.60 |
| 52 Weeks Range | |
| Earnings Date | 3 Nov 2026 |
| Diluted EPS (TTM) | -3.54 |
| Total Debt/Equity (MRQ) | 27.58% |
| Current Ratio (MRQ) | 2.26 |
| Operating Cash Flow (TTM) | -113.53 M |
| Levered Free Cash Flow (TTM) | -74.11 M |
| Return on Assets (TTM) | -74.21% |
| Return on Equity (TTM) | -156.81% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Biomea Fusion, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -2.5 |
| Relative Valuation | NA |
| Financial Health | NA |
| AI Insight | NA |
| Weighted Average | -0.67 |
Select this tab to load the latest available analysis.
|
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 9.76% |
| % Held by Institutions | 45.04% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Fideuram - Intesa Sanpaolo Private Banking S.P.A. | 30 Jun 2026 | 723,176 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |